KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Shares Repurchased (2018 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Shares Repurchased for 9 consecutive years, with $794.3 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Repurchased fell 23.73% year-over-year to $794.3 million; the TTM value through Mar 2026 reached $3.2 billion, down 4.83%, while the annual FY2025 figure was $3.4 billion, 32.09% up from the prior year.
  • Shares Repurchased hit $794.3 million in Q1 2026 for Regeneron Pharmaceuticals, up from $671.7 million in the prior quarter.
  • Across five years, Shares Repurchased topped out at $1.1 billion in Q2 2025 and bottomed at $289.0 million in Q4 2023.
  • Average Shares Repurchased over 5 years is $656.1 million, with a median of $671.7 million recorded in 2025.
  • Year-over-year, Shares Repurchased surged 461.66% in 2022 and then plummeted 59.01% in 2024.
  • Regeneron Pharmaceuticals' Shares Repurchased stood at $431.1 million in 2022, then crashed by 32.96% to $289.0 million in 2023, then surged by 236.68% to $973.0 million in 2024, then plummeted by 30.97% to $671.7 million in 2025, then grew by 18.25% to $794.3 million in 2026.
  • According to Business Quant data, Shares Repurchased over the past three periods came in at $794.3 million, $671.7 million, and $664.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.